Disease characteristics and serological responses in patients with differing severity of COVID-19 infection: A longitudinal cohort study in Dhaka, Bangladesh

Author:

Akter Afroza,Ahmed Tasnuva,Tauheed Imam,Akhtar Marjahan,Rahman Sadia Isfat AraORCID,Khaton Fatema,Ahmmed Faisal,Ferdous JannatulORCID,Afrad Mokibul HassanORCID,Kawser Zannat,Hossain Mohabbat,Khondaker RabeyaORCID,Hasnat Mohammad Abul,Sumon Mostafa AzizORCID,Rashed AsifORCID,Ghosh Shuvro,Calderwood Stephen B.,Charles Richelle C.,Ryan Edward T.,Khatri PurveshORCID,Maecker Holden TerryORCID,Obermoser Gerlinde,Pulendran Bali,Clemens John D.ORCID,Banu Sayera,Shirin TahminaORCID,LaRocque Regina C.,Harris Jason B.ORCID,Bhuiyan Taufiqur Rahman,Chowdhury Fahima,Qadri FirdausiORCID

Abstract

Background COVID-19 caused by SARS-CoV-2 ranges from asymptomatic to severe disease and can cause fatal and devastating outcome in many cases. In this study, we have compared the clinical, biochemical and immunological parameters across the different disease spectrum of COVID-19 in Bangladeshi patients. Methodology/Principal findings This longitudinal study was conducted in two COVID-19 hospitals and also around the community in Dhaka city in Bangladesh between November 2020 to March 2021. A total of 100 patients with COVID-19 infection were enrolled and classified into asymptomatic, mild, moderate and severe cases (n = 25/group). In addition, thirty age and sex matched healthy participants were enrolled and 21 were analyzed as controls based on exclusion criteria. After enrollment (study day1), follow-up visits were conducted on day 7, 14 and 28 for the cases. Older age, male gender and co-morbid conditions were the risk factors for severe COVID-19 disease. Those with moderate and severe cases of infection had low lymphocyte counts, high neutrophil counts along with a higher neutrophil-lymphocyte ratio (NLR) at enrollment; this decreased to normal range within 42 days after the onset of symptom. At enrollment, D-dimer, CRP and ferritin levels were elevated among moderate and severe cases. The mild, moderate, and severe cases were seropositive for IgG antibody by day 14 after enrollment. Moderate and severe cases showed significantly higher IgM and IgG levels of antibodies to SARS-CoV-2 compared to mild and asymptomatic cases. Conclusion/Significance We report on the clinical, biochemical, and hematological parameters associated with the different severity of COVID-19 infection. We also show different profile of antibody response against SARS-CoV-2 in relation to disease severity, especially in those with moderate and severe disease manifestations compared to the mild and asymptomatic infection.

Funder

Bill and Melinda Gates Foundation

Publisher

Public Library of Science (PLoS)

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Reference44 articles.

1. Antibody responses after COVID-19 infection in patients who are mildly symptomatic or asymptomatic in Bangladesh;T Shirin;Int J Infect Dis,2020

2. Genomic and mobility data reveal mass population movement as a driver of SARS-CoV-2 dissemination and diversity in Bangladesh;LA Cowley;medRxiv,2021

3. Nearly 20 lakh Dhaka residents could be Covid-19 positive, 78% asymptomatic: study. The Daily Star. 11 Aug 2020. https://www.thedailystar.net/coronavirus-deadly-new-threat/news/nearly-20-lakh-dhaka-residents-could-be-covid-19-positive-78-asymptomatic-study-1942953. Accessed 26 Aug 2020.

4. WHO Coronavirus (COVID-19) Dashboard. [cited 20 May 2021]. https://covid19.who.int

5. Bangladesh COVID-19 Hospital Information. 17 Aug 2020 [cited 17 Aug 2020]. https://dghs.gov.bd/images/docs/Notice/2020/corona/covid19_hospital_information.pdf

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3